Combinations of Targeted Therapies Take Aim at Multiple Pathways

Combinations of targeted therapies in human cancers

human cancers are driven by one specific molecular event, such as, for example, chronic myeloid leukemia. Human cancers appear to be generally derived from multiple oncogenic alterations maturing through their own particular mechanisms [1]. One major consequence of such alterations is the dysregulation of intracellular signaling pathways favoring tumor cell survival, proliferation, and motility...

T cells take aim at cancer.

E since Paul Ehrlich introduced the term ‘‘magic bullet,’’ the exquisite capacity for specificity afforded by the immune system has always underpinned its appeal as a therapeutic weapon against cancer. The first clinical validation of this principle came in the form of mAb administration, which, after a decade of skepticism, produced therapeutic successes in breast cancer and B cell lymphomas. ...

Companies Take Aim at MRSA Infections.

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most widespread and virulent nosocomial pathogens. The late-stage clinical pipeline includes an array of proposed new treatments aimed at MRSA-related skin infections and pneumonia.

Big guns take aim at wide - bandgap sector

'Populist politicians' take aim at 'soft-target' doctors.